Jefferies Remains Sidelined on Karyopharm Therapeutics (KPTI) Following 4Q - PT to $10

March 15, 2016 8:39 AM

Jefferies reiterated a Hold rating on Karyopharm Therapeutics (NASDAQ: KPTI), and cut the price target to $10.00 (from $14.00), following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found